Apr 6, 2009, 6:20 AM
- The consistency lots of the new meningococcal A (MenA)
conjugate vaccine for the Phase 3 clinical trials have been released by Serum
Institute of India Limited (SIIL),
- Good progress continues to be made towards completing the
regulatory file. The aim is to submit the file to the Drugs Controller General
- The PsA-TT-001 clinical study in
- The PsA-TT-002 clinical study in
- The PsA-TT-003 clinical study in
- The PsA-TT-004 clinical study started at Navrongo Health
- Preparations for the PsA-TT-005 clinical study in
- The MVP clinical team developed a draft protocol for
PsA-TT-006, a large Phase 3 safety study that will take place in
- A serology meeting
took place in
Surveillance and Epidemic Preparedness Activities
- At the beginning of the epidemic season, the WHO
Multi-Disease Surveillance Centre (MDSC) team in
- On November 12-21, the MDSC team made a follow-up country visit to the Democratic Republic of the Congo (DRC) to provide a refresher training course on the standard operating procedures for enhanced surveillance of meningococcal meningitis. While DRC lies outside the official meningitis belt, the increasing number of cases reported in the country (6,125 suspected cases of meningitis from January 1 - December 28) is consistent with the suspicion that the African meningitis belt may be expanding southward and affecting regions that have been spared until now.
- The MDSC team organized workshops on standard operating
procedures for enhanced surveillance of meningococcal meningitis in
During these visits, the team revised the national work plan for meningitis activities and provided technical support to ministry of health surveillance units. Local surveillance staffs were trained on data management and laboratory techniques to identify disease-causing serogroups.
- An advanced draft of the new guidelines for case-based
surveillance of meningococcal meningitis in the African meningitis belt has
been finalized. Under the old system suspected cases were reported. Under the
new guidelines, confirmed cases are reported with complete epidemiological and
laboratory data. The new system should improve understanding of epidemic
- The MDSC team in collaboration with the WHO office in
Vaccine Introduction Strategy and Communication
- MVP worked in close collaboration with WHO's Health,
Information, and Promotion office to organize a communicators' workshop in
About 30 professional health communicators and media representatives participated in the workshop that provided information related to the launch of the Ghanaian infant study.
Prof. Francis Nkrumah, chairman of the Project Advisory
Group, spoke at the opening ceremony that was presided over by Dr. Daniel
Kertesz, the new WHO representative in
Both reminded communicators about the crucial role they play
in informing the community about the clinical study and the new vaccine. Mr.
Jean-Marc Fleury, executive director of the Quebec-based World Federation of
Science Journalists also attended the workshop to explore ways to develop
health- and vaccine-related media coverage in
- The MVP team developed a communication plan to support the
carriage study in
- After approving US$55 million for the immediate creation
of a meningococcal a vaccine emergency stockpile, the GAVI Alliance Board
approved US$29 million for the introduction of the MenA conjugate vaccine in
three meningitis belt countries (
- MVP held its annual workshop in
That's all for now from the MVP team. Stay tuned for our next news digest in three months' time.
We look forward to receiving your comments email@example.com.
Created in 2001, the Meningitis Vaccine Project is a
partnership between WHO and PATH. The mission of MVP is to eliminate epidemic
meningitis as a public health problem in sub-Saharan
For more information on MVP, please visit our website at http://www.meningvax.org.